Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)

  • Emma M. Kileel
  • , Carlos D. Malvestutto
  • , Janet Lo
  • , Kathleen V. Fitch
  • , Carl J. Fichtenbaum
  • , Judith A. Aberg
  • , Markella V. Zanni
  • , Esteban Martinez
  • , Nwora Lance Okeke
  • , Princy Kumar
  • , Esau Joao
  • , Sara H. Bares
  • , Daniel Berrner
  • , Marek Smieja
  • , Jhoanna C. Roa
  • , Sara McCallum
  • , Pamela S. Douglas
  • , Heather J. Ribaudo
  • , Steven K. Grinspoon

Research output: Contribution to journalArticlepeer-review

6 Scopus citations

Abstract

Over 2-years of follow-up, integrase strand transfer inhibitor (INSTI)-use was associated with weight gain among those on an INSTI <2 years at entry (+0.27 kg/m2/year; 95% confidence interval [CI],. 22 to. 33 vs +0.17 kg/m2/year; 95% CI,. 12 to. 23; P =. 01), but not those on an entry INSTI >2 years.

Original languageEnglish
Pages (from-to)2010-2013
Number of pages4
JournalClinical Infectious Diseases
Volume76
Issue number11
DOIs
StatePublished - 1 Jun 2023

Keywords

  • HIV
  • body mass index (BMI)
  • integrase strand transfer inhibitors (INSTIs)
  • weight

Fingerprint

Dive into the research topics of 'Changes in Body Mass Index with Longer-Term Integrase Inhibitor Use: A Longitudinal Analysis of Data from the Randomized Trial to Prevent Vascular Events in Human Immunodeficiency Virus (REPRIEVE)'. Together they form a unique fingerprint.

Cite this